SAB Biotherapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -752 | -763 | -765 | |
EBITDA | -21,629 | -18,053 | -16,033 | 46,254 |
EBIT | -22,429 | -18,806 | -16,797 | 45,488 |
Net Income | -22,491 | -18,868 | -16,860 | 45,445 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -26,681 | -15,254 | -17,710 | -13,050 |
Cash | 8,267 | 20,519 | 10,502 | 29,424 |
Basic Shares | 79,753 | 53,558 | 47,609 | 77,863 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $1,322 | $2,239 | $23,904 |
Gross Profit | -3,081 | -3,470 | -1,506 | 20,612 |
EBITDA | 16,595 | -28,994 | -38,133 | -15,122 |
EBIT | 13,514 | -33,786 | -41,878 | -18,414 |
Net Income | 13,273 | -34,105 | -42,194 | -18,741 |
Net Change In Cash | 0 | 1,322 | 2,239 | 23,904 |
Cost of Revenue | -24,498 | |||
Free Cash Flow | -45,709 | -34,629 | -25,316 | -25,625 |
Cash | 10,502 | 8,897 | 56,566 | 15,046 |
Basic Shares | 61,340 | 9,262 | 5,521 | 4,352 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.28 |
2026-03-31 | -$0.35 |
2025-12-31 | -$0.41 |
2025-09-30 | $0.50 |